DHODH and multiple sclerosis: Given that the DHODH inhibitor teriflunomide is an FDA- and EU-approved drug for the treatment of multiple sclerosis, with favorable long-term safety data [67], and that it proved highly efficient at inhibiting EBOV infection in vitro, it will be of great interest to test this compound in animal models for EBOV infection.